European mid-sized pharma companies – the sweet spot between biotechs and big pharma?

9 March 2018

Ed Corbett, principal and commercial practice lead at specialist management consultancy firm Novasecta, makes the case for an oft-forgotten part of the pharma ecosystem in an exclusive Expert View piece.

Historically, focus on the pharmaceutical industry has been split between up-and-coming biotechs and big pharma behemoths.

Both have compelling narratives that are attractive to investors, healthcare professionals and patients. All too often however, the companies in between the two, the mid-sized pharmaceutical companies with revenues of 50 million euros ($61.5 million) to five billion euros ($6.2 billion), get overlooked. These companies have their own, distinct stories. When investigated, these stories have lessons for biotechs and big pharma alike.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK